SCHEMBL2522175

SCHEMBL2522175

C(=N/Nc1cccc2cccnc12)\c1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 14/20 0.64
▸ MAPT P10636 12/20 0.64
▸ KMT2A Q03164 12/20 0.64
▸ MEN1 O00255 11/20 0.64
▸ TDP1 Q9NUW8 10/20 0.64
▸ SMN1; SMN2 Q16637 7/20 0.64
▸ NPC1 O15118 7/20 0.64
▸ RAB9A P51151 7/20 0.64
▸ KDM4E B2RXH2 6/20 0.64
▸ ATM Q13315 1/20 0.62
▸ NFKB1 P19838 5/20 0.61
▸ NFKB2 Q00653 5/20 0.61
▸ RELA Q04206 5/20 0.61
▸ HPGD P15428 3/20 0.61
▸ ALDH1A1 P00352 4/20 0.56
▸ SENP7 Q9BQF6 6/20 0.55
▸ LMNA P02545 5/20 0.55
▸ L3MBTL1 Q9Y468 5/20 0.55
▸ SENP8 Q96LD8 4/20 0.55
▸ SENP6 Q9GZR1 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2521031 1.00 GAA (0.64) GAAMAPTKMT2AMEN1TDP1
SCHEMBL12214431 0.83 SENP7 (0.65) GAAMAPTKMT2AMEN1TDP1
SCHEMBL24629292 0.79 GAA (0.75) GAAMAPTKMT2AMEN1TDP1
SCHEMBL27135266 0.79 GAA (0.75) GAAMAPTKMT2AMEN1TDP1
SCHEMBL30711838 0.76 SENP7 (0.71) GAAMAPTKMT2AMEN1TDP1
SCHEMBL27129941 0.76 SENP7 (0.71) GAAMAPTKMT2AMEN1TDP1
SCHEMBL24629108 0.76 SENP7 (0.71) GAAMAPTKMT2AMEN1TDP1
SCHEMBL5405166 0.73 MAPT (0.65) GAAMAPTKMT2AMEN1TDP1
SCHEMBL24629300 0.72 SENP7 (1.00) GAAMAPTKMT2AMEN1TDP1
SCHEMBL27139059 0.72 SENP7 (1.00) GAAMAPTKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039505-B2 Compounds for modulating T-cells UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-18 — — US disclosed
US-8039505-B2 Compounds for modulating T-cells UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-18 — — US disclosed
US-8039505-B2 Compounds for modulating T-cells UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-18 — — US disclosed
US-20080293739-A1 COMPOUNDS FOR MODULATING T-CELLS UNIVERSITY OF UTAH RESEARCH FOUNDATION 2008-11-27 — — US disclosed
US-20080293739-A1 COMPOUNDS FOR MODULATING T-CELLS UNIVERSITY OF UTAH RESEARCH FOUNDATION 2008-11-27 — — US disclosed
US-20080293739-A1 COMPOUNDS FOR MODULATING T-CELLS UNIVERSITY OF UTAH RESEARCH FOUNDATION 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293739-A1 COMPOUNDS FOR MODULATING T-CELLS CD4, HLA-DRB1, CD74 GAA 4266/4885MAPT 3438/4885KMT2A 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback